Tag Archive for: inflammation

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

/in

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance Montreal, Canada – Strasbourg, France – Boston, United States, March 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

Read more

Resolve M Therapeutics exits from stealth

/in

Unique platform designed to engage pro-resolution responses to restore immune homeostasis in inflammatory disorders without broad immuno-suppression. Cambridge, MA, USA, January 22, 2026 – Resolve M Therapeutics, Inc., the biotech aiming to build the world’s first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its […]

Read more

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies

/in

Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of corporate growth Kainova champions scientific agility, bold ambition, and unity of purpose Montreal, Canada, Strasbourg, France, Boston, USA, January 12, 2026: Kainova Therapeutics (“Kainova” or “the Company”), a catalyst for breakthrough treatments for patients in immuno-oncology and inflammation, today announced a transformative rebrand. The new […]

Read more

Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer

/in

Internationally recognized clinical strategist with proven track record in translating innovation into clinical impact joins Domain to advance its GPCR-targeting pipeline Appointment comes at a pivotal moment, following the initiation of Phase I/II development of DT-7012, a Treg-depleting anti-CCR8 antibody candidate Strasbourg, France – Montreal, Canada – Boston, United States, November 13, 2025: Domain Therapeutics […]

Read more

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize

/in

Awarded in recognition of excellence in research and innovation and contribution to scientific progress Reflects the revolutionary potential of Curve’s gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targets Southampton, UK, 25 June 2025 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and […]

Read more